Sedgwick: Five Industries Saw Higher US Recall Volumes in 2025

Why It Matters

Elevated recall activity signals tightening regulatory scrutiny and rising compliance costs, forcing companies to adapt supply‑chain and quality‑control practices. The trends foreshadow heightened risk exposure and strategic shifts for manufacturers and distributors.

Key Takeaways

• 3,295 total recalls across five sectors in 2025.
• Consumer products hit decade‑high with 414 recalls.
• FDA food recalls reached 517, highest in nine years.
• Automotive recalls fell but Q4 rose 17% despite fewer units.
• New tariffs and cGMP guidance increase compliance costs.

Pulse Analysis

The 2026 Sedgwick State of the Nation report underscores a pivotal shift in U.S. product safety dynamics, with recall volumes climbing across consumer‑facing sectors. While automotive and medical device recalls modestly declined, the overall spike reflects intensified regulatory enforcement and a broader industry push toward transparency. Companies are now navigating a landscape where delayed defect reporting triggers steep fines, prompting faster, more rigorous internal audit cycles and heightened collaboration with agencies such as the FDA and USDA.

Consumer products and food & drink categories drove the surge, each confronting unique challenges. The consumer products sector recorded its most recalls in over ten years, a trend linked to tighter safety standards and increased consumer vigilance. Simultaneously, FDA food recalls surged to 517, the highest in nine years, while USDA recalls rose 20%, highlighting supply‑chain vulnerabilities from raw material sourcing to final packaging. These pressures have spurred manufacturers to adopt advanced traceability technologies and bolster batch‑level quality controls to mitigate future disruptions.

The automotive sector illustrates how trade policy intertwines with safety compliance. Despite a 13‑year low in total recalled units, the fourth quarter experienced a 17.2% rise in recall filings, driven largely by equipment failures. Concurrently, 25% tariffs on trucks and parts, alongside new duties on steel and aluminum, compel automakers to reassess sourcing strategies and domestic production footprints. Coupled with FDA’s new cGMP guidance for pharmaceuticals, the regulatory environment demands agile, forward‑looking risk management, positioning firms that can swiftly adapt as competitive advantage in 2026 and beyond.